These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 23152253)

  • 1. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
    Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab for patients with chronic lymphocytic leukaemia.
    Skoetz N; Bauer K; Elter T; Monsef I; Roloff V; Hallek M; Engert A
    Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD008078. PubMed ID: 22336834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance therapy for chronic lymphocytic leukaemia.
    Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
    Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib for the treatment of multiple myeloma.
    Scott K; Hayden PJ; Will A; Wheatley K; Coyne I
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD010816. PubMed ID: 27096326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
    Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
    Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
    Sickinger MT; von Tresckow B; Kobe C; Engert A; Borchmann P; Skoetz N
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010533. PubMed ID: 25572491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)).
    Küley-Bagheri Y; Kreuzer KA; Monsef I; Lübbert M; Skoetz N
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD011960. PubMed ID: 30080246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
    Hoyle M; Crathorne L; Garside R; Hyde C
    Health Technol Assess; 2011 May; 15 Suppl 1():61-7. PubMed ID: 21609654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.
    Lee CH; Chen PH; Lin C; Wang CY; Ho CL
    PLoS One; 2020; 15(1):e0226879. PubMed ID: 31995577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
    Woyach JA; Ruppert AS; Rai K; Lin TS; Geyer S; Kolitz J; Appelbaum FR; Tallman MS; Belch AR; Morrison VA; Larson RA; Byrd JC
    J Clin Oncol; 2013 Feb; 31(4):440-7. PubMed ID: 23233702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
    Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
    Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
    Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes.
    Hutzschenreuter F; Monsef I; Kreuzer KA; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009310. PubMed ID: 26880256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.